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Objective: Studies have shown antidepressants are no better than placebo in treating depression in dementia. We examined antidepressant efficacy in subgroups of depression in dementia with different depressive symptom profiles. 
Design: Exploratory secondary analyses on the randomised, parallel-group, double-blind, placebo-controlled Health Technology Assessment Study of Antidepressants for Depression in Dementia trial (HTA-SADD). 
Setting: old-age psychiatry services in nine centers in England. 
Participants: 326 patients meeting NINCDS-ADRDA probable/possible Alzheimer’s disease criteria, and Cornell Scale for Depression in Dementia (CSDD) scores ≥8. 
Intervention: Placebo (n=111), sertraline (n=107), or mirtazapine (n=108). 
Measurements: Latent class analyses (LCA) on baseline CSDD-items clustered participants into symptom-based subgroups. Mixed-model analysis evaluated CSDD-improvement at 13 and 39 weeks by randomization in each subgroup.
Results: LCA yielded 4 subgroups: ‘severe’ (n=34), ‘psychological’ (n=86), ‘affective’ (n=129), and ‘somatic’ (n=77). Mirtazapine, but not sertraline, outperformed placebo in the psychological subgroup at week 13 (adjusted estimate: -2∙77 (SE 1∙16; 95% CI -5∙09 to -0∙46)), which remained, but lost statistical significance, at week 39 (-2∙97 (SE 1∙59; 95% CI -6∙15 to 0∙20)). Neither sertraline nor mirtazapine outperformed placebo in the other subgroups.
Conclusions:  Due to the exploratory nature of the analyses and the small sample sizes for subgroup analysis there is the need for caution in interpreting these data. Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with ‘psychological’ symptoms would be valuable. These data should not change clinical practice but future trials should consider stratifying types of depression in dementia in secondary analyses.






Depression is common in dementia with prevalence of depressive symptoms in people with dementia ranging between 10 and 62%.1 Depression in dementia is associated with reduced quality of life,2 exacerbation of cognitive and functional impairment,3 and increased stress and depression in caregivers.4 Effective treatment of depression in dementia is therefore a clinical priority. Older clinical guidelines advocate the use of antidepressants for depression in dementia such as the APA workgroup on Alzheimer's Disease and other dementia's (2007)5 and as many as 22-47% of community-dwelling persons with dementia are prescribed antidepressants.6,7 However, the current evidence from well-designed placebo-controlled trials as summarized in the most recent 2018 Cochrane review8, suggests that some early and small trials found positive results while larger more recent studies have been largely negative and that, on balance, there is little evidence of the efficacy of antidepressants for depression in dementia.  They found that of the 8 studies reviewed which included 614 participants in total, the only study that showed significant benefit of antidepressant over placebo on average depressive symptom severity was the small DIADS study (Lyketsos et al 2003). This study showed a significant benefit of sertraline over placebo on average depressive symptom severity at 12 weeks in 44 participants. However, the other 7 studies, including the follow-up DIADS-II study9,10 showed no beneficial effects of antidepressants over placebo, resulting in a pooled effect size of -0.13 (95% CI: -0.33 – 0.07) for SSRIs and -0.10 (95% CI: -0.26 – 0.06) for antidepressants in general.  There is however evidence that antidepressants are associated with more adverse events than placebo.8,11,12 It is also the case that relatively few antidepressants have been trialed in depression in dementia and that further investigation is needed, particularly of newer medications.8 As a response to this emerging evidence, the most recent guidelines suggest that antidepressants should not be routinely offered as a first line treatment to those with mild to moderate depression in dementia (NICE, 2018).13

The Health Technology Assessment Study of the Use of Antidepressants for Depression in Dementia (HTA-SADD) trial was a large randomized controlled trial of the efficacy of sertraline (n=107) and mirtazapine (n=108) versus placebo (n=111) in people with probable or possible Alzheimer’s disease and depression.14 In all three groups, an improvement in total Cornell Scale for Depression in Dementia (CSDD)15 scores was seen from week 0 to week 13, which persisted to week 39. However, sertraline and mirtazapine did not outperform placebo. This lack of observed antidepressant efficacy may in part be due to the heterogeneity of depression in dementia.11 Therefore, there may be value in evaluating antidepressant efficacy in subgroups of depression in dementia. 

Different symptoms of depression in dementia may have a different underlying aetiology. Some depressive symptoms, for example, may occur as a reaction to perceived cognitive deficits whereas others may have a common underlying (neuro)pathology with cognitive deficits.16 For instance, vascular disease and a disruption of frontal-subcortical pathways may underlie both motivational-related symptoms of depression (i.e. loss of interest in activities, psychomotor retardation) and executive deficits.17 Also, the substantial overlap of symptoms of depression and dementia (e.g. psychomotor change, apathy, lack of interest, sleep difficulties, concentration problems)18,19,20 make it possible that symptoms of dementia are misclassified as symptoms of depression. Because different symptoms of depression in dementia may have a different underlying aetiology, response to antidepressant treatment might differ according to the depressive symptom profile of the patient. It would therefore be of clinical relevance if it were possible to identify subgroups of patients who might be more likely to respond to antidepressants based on their symptom profile. 

Aims of the study






Study design and participants
HTA-SADD was a randomized double-blind placebo-controlled trial to evaluate the clinical effectiveness of sertraline and mirtazapine in those with depression in dementia. Details of this study have been reported previously.14 Participants were recruited from old-age psychiatry services in nine centers in England. Inclusion criteria were: 1) National Institute of Neurological and Communicative Diseases and Stroke (NINCDS)-Alzheimer’s Disease and Related Disorders Association (ADRDA) criteria for probable or possible Alzheimer’s disease,21 2) co-existing depression of at least 4 weeks duration assessed as potentially needing antidepressants as ascertained by the referring psychiatrist (however, diagnostic criteria for major depressive disorder were not evaluated), and 3) a CSDD-score of 8 or more ascertained by a trained research worker. Exclusion criteria were: 1) clinically too critical for randomization (e.g. suicide risk), 2) absolute contraindication to trial drugs, 3) already using antidepressants, 4) in another trial, and 5) no family or professional caregiver informant. The study was approved by the North West 7 (Greater Manchester, UK) ethics committee, and consent or assent was obtained from all participants. The study is registered under ISRCTN88882979 and EudraCT 2006-000105-38.

Randomisation and masking
Participants were independently allocated to receive placebo, sertraline or mirtazapine in a ratio of 1:1:1. Randomization was stratified by centre (n=9) using a computer-generated randomization sequence with randomly varying block sizes of 3 or 6. The trial was double-blind: patients, referring clinicians, research workers who did baseline and follow-up assessments, and statisticians were masked to group identity. The researcher performing the secondary analyses in this paper was not masked for group identity.

Dosages of mirtazapine and sertraline
Patients in the sertraline and mirtazapine group started on 50 mg for sertraline and 15 mg for mirtazapine. Over the first two weeks, the dosage was increased to 100 mg for sertraline and 30 mg for mirtazapine. At 4 weeks, the CSDD was re-administered: if the CSDD score was 4 or higher the dosage was increased to the maximum of 150 mg for sertraline and 45 mg of mirtazapine. If the CSDD was below 4 the CSDD was administered again at 8 weeks, and the dosage was increased to 150 and 45 mg if the score was 4 or higher. After 8 weeks, clinicians were free to adjust the dose.

Assessment of depressive symptoms
At baseline, at 13 and 39 weeks after baseline the CSDD15 was administered by a trained research worker, who interviewed both the patient and the caregiver. The CSDD 19 questions which can be rated 0 (absent), 1 (mild) or 2 (severe). The total score therefore ranges from 0 to 38, with higher scores denoting higher severity of depression. 

Baseline characteristics
The following caregiver-rated scores were completed at baseline, prior to randomisation: participant quality of life (SF-12 mental and physical subscales, EuroQOL-VAS and DEMQOL-Proxy), participant activity limitation (BADL), participant neuropsychiatric symptoms (NPI), caregiver mental health (GHQ-12), and caregiver burden (Zarit). The following participant-rated scores were assessed at baseline: participant cognition (MMSE), and participant quality of life (EuroQOL VAS and DEMQOL). To assess dementia vascularity, a modified Hachinski score was calculated at baseline.

Analyses
All participants that were included at baseline (n=326) were classified into different classes according to their endorsed symptom profile by performing LCA22,23 on the 19 items of the baseline CSDD. Before entering into the LCA, responses to the CSDD items were dichotomized into absent or present. Models with one to six classes were fitted using maximum likelihood estimator with robust standard errors. The optimal number of classes was determined by comparing fit statistics, interpretability of the classes, and absence of overly small classes (n<30). Details of the LCA can be found in the Supplemental file. 







A total of 326 participants were randomized to placebo (n=111), sertraline (n=107) and mirtazapine (n=108). At 13 weeks, 258 completed the CSDD (placebo: n=95; sertraline: n=78; mirtazapine: n=85), and at 39 weeks 226 (placebo: n=82; sertraline: n=68; mirtazapine: n=76). 

Results of the LCA
The optimal solution of the LCA yielded 4 classes: 1) a ‘severe’ class, 2) a ‘psychological’ class with relatively severe endorsement of psychological symptoms (pessimism and low self-esteem) and absence of sleep problems, 3) an ‘affective’ class with relatively low endorsement of psychological items and absence of appetite problems, and 4) a ‘somatic’ class with mainly somatic symptoms and less affective/mood symptoms (see Supplementary Figure 1). Details of the LCA results and the selection of the optimal number of classes can be found in the Supplementary file.

Baseline characteristics for each of the 4 classes (Table 1)
Patients in class 1 (severe symptoms) had worse quality of life scores, worse total CSDD-scores, and higher NPI scores on depression and anxiety compared to patients in all other 3 classes. They also had higher scores on NPI appetite/eating disorders compared to patients in classes 2 and 3 (psychological and affective symptoms respectively), and worse BADL-scores compared to patients in class 2 (psychological symptoms). Patients in class 4 (somatic symptoms) had worse total CSDD-scores than patients in class 2 (psychological symptoms) (see Table 1).

Impact of randomization arm on course over time of total CSDD scores in each class






This is the first study to explore antidepressant efficacy in subgroups of depression in dementia with different depressive symptom profiles. In these exploratory secondary analyses we identified that a ‘psychological’ subgroup with affective symptoms, relatively severe endorsement of psychological symptoms (pessimism and low self-esteem) and an absence of sleep problems appeared to respond better to mirtazapine compared with placebo. Those in this ‘psychological’ subgroup receiving mirtazapine improved on average almost three CSDD points (95% CI: -5.1 - to -0.5 points) more than those receiving placebo from week 0 to week 13, which was sustained to week 39. At week 39 the difference with baseline was as high as at week 13, but lost statistical significance due to smaller group sizes. The beneficial effects of mirtazapine compared to placebo in this group correspond to effect sizes (SE) of 0∙70 (0.31) at week 13 and 0∙65 (0.34) at week 39, which would be considered moderate or medium effect sizes. Antidepressant treatment was not effective in reducing depression in any of the other subgroups. It is important to note that this is an exploratory secondary analysis from a study where the primary findings were negative.  As such these data are in no way definitive and would benefit from replication. 

Comparison to literature
In the Depression in Alzheimer’s Disease Study (DIADS) of 44 people with depression in Alzheimer’s Disease, response to sertraline was observed to be highest on the mood subscale of the CSDD compared with other instruments.26 In the larger DIADS-2 there was no differential response to sertraline compared with placebo in subgroups of depression in dementia with 1) major depression, 2) minor depression, and 3) Alzheimer’s associated affective disorder.27 

Studies have evaluated antidepressant efficacy on specific depressive symptoms and symptom profiles in depressed populations without dementia. Depressed patients without dementia were not the subject of this study and there will be major limitations in generalizability from populations without dementia to those with dementia. However, these studies do provide an illustration of the potential for exploration of differential response in subgroups of people with depression.  A pooled analysis from 32 RCTs evaluating the efficacy of an SSRI against placebo found that SSRIs were more effective in improving mood than in reducing other symptoms of depression.28 Secondary analyses from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) and the Combining Medications to Enhance Depression Outcomes (CO-MED) trials showed that core emotional symptoms (low mood, loss of interest, feelings of worthlessness) responded better to antidepressants than sleep symptoms, and sleep symptoms responded better to antidepressants than atypical symptoms (suicidality, psychomotor agitation/retardation and hypersomnia).29 The efficacy of antidepressant treatment on these different symptom clusters differed according to drug. For instance, core emotional symptoms responded better to high-dose duloxetine and paroxetine than escitalopram, which performed equal to placebo in reducing core emotional symptoms.29 In the Genome Based Therapeutic Drugs for Depression (GENDEP) study, mood and cognitive symptoms improved more with escitalopram than with nortriptyline whereas neurovegetative symptoms improved more with nortriptyline than escitalopram.30 In an RCT of 231 depressed patients, paroxetine treatment and cognitive therapy were associated with a greater reduction in cognitive/suicide symptoms relative to placebo, and cognitive therapy was associated with a greater reduction in atypical-vegetative symptoms than placebo or paroxetine.31 

While these specific findings cannot be generalized directly to depression in dementia, taken with the data presented here, it is possible that antidepressant treatments may be more beneficial for patients with relatively high endorsement of core mood and psychological symptoms than for patients with more other (e.g. vegetative or atypical) symptoms of depression.  

Interpretation and clinical implications
The results of the present analyses should be interpreted with caution, because they are based on exploratory secondary analyses in small groups. Small group size, or lack of power, not only results in false negative findings, but also may result in false positive findings.32 Before making any conclusions, it is therefore essential that these results are replicated. Furthermore, it is counterintuitive that mirtazapine (a sedating drug that is often prescribed in patients with sleep problems) was effective in a subgroup without sleep problems, while sertraline is not effective in reducing depression in any of the 4 subgroups. This counterintuitive finding requires further investigation. 

Another methodological issue is that patients in all three arms, including the placebo-group, improved considerably. This improvement may be due to artifacts such as regression to the mean, the Hawthorne effect or the natural course of depression in dementia. This last possibility is less likely because 221 of 326 participants had been depressed for more than 6 months before randomization. Perhaps the greatest contributor to the improvements in depression is the non-drug treatment as usual by the old-age psychiatry services. This treatment as usual is personalized, including a broad range of supportive and problem-solving interventions, and is commonly delivered by a community psychiatric nurse in the patient’s own household. Antidepressants may not be effective over and above the effects of this personalized non-drug intervention.

In the context of conflicting conclusions in clinical guidelines,5,13 clinicians should continue to be cautious in prescribing antidepressants in people with dementia. Surprisingly, in the ‘severe’ depression subgroup, no beneficial effects of sertraline and mirtazapine were found at 13 weeks, with worse (but statistically non-significant) effects at 39 weeks. This is important as general guidelines for treatment of clinical depression33,34 as well as the updated clinical guideline NICE 2018 for depression in dementia13 have different guidelines according to initial depression severity, and thus physicians generally rely on the severity of the depression rather than symptom profile when starting drug treatment. However, a recent individual patient data meta-analysis also concluded that antidepressant efficacy does not differ according to initial depression severity.35 

Strengths and limitations
This study uses the data from the largest completed double blind randomized placebo-controlled trial of depression in dementia. Due to the large sample size, we were able to explore antidepressant efficacy in subgroups of depression in dementia. However these results must also be interpreted with caution. The first and most important limitation of the analyses reported here is that this is a set of secondary analyses and the sample size for these subgroup analyses is smaller than for the primary outcomes. The relatively small sizes of the subgroups and the number of analyses may have resulted in both lack of power, and positive findings due to chance. Therefore, the results reported should be interpreted cautiously and before making any conclusions, replication of these findings is needed. Second, while data driven, the interpretation of the LCA and the choice of the optimal number of classes has an element of subjectivity. The 4-class model was chosen based on the BLRT and the interpretability of the classes of the 4-class model and the small sample sizes of the 5- and 6-class models. However, the BIC preferred the 2-class model. Third, the study included only sertraline and mirtazapine, while studies in depressed non-demented populations have found evidence that efficacy on specific symptoms might vary for different antidepressants. Fourth, data on non-drug interventions outside the study protocol were not gathered. There is a possibility that the observed differences might have been influenced by non-drug treatments for depression outside the study protocol, however the randomization should have assorted these equally across the three intervention groups.   

Conclusions
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Figure 1: unadjusted mean CSDD scores by treatment group for each class separately
Class 1: severe; class 2: psychological; class 3: affective; class 4: somatic. Lowest score is best. Error bars show 95% CI’s. CSDD=Cornell Scale for Depression in Dementia. 
*difference with placebo: p<.05
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